Clinical Trials Browser

Phase 3 × Carcinoma, Transitional Cell × Ramucirumab × Clear all

NCT02426125 2023-08-21

RANGE

Phase 3 Completed

530 enrolled 22 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urethral Neoplasms